Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Rectal Neoplasms 4Gliosarcoma 4Glioblastoma 4Central Nervous System Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Kidney Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Leukemia 2Breast Neoplasms 2Brain Neoplasms 2Tongue Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Precancerous Conditions 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukoplakia, Oral 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Docetaxel 6Erlotinib Hydrochloride 5Cetuximab 5Magnetic Resonance Spectroscopy 4Radiotherapy 3Cisplatin 3Biopsy 3Vorinostat 2Trastuzumab 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2SS1(dsFv)PE38 2Radiation 2Paclitaxel 2Immunohistochemistry 2Hydroxyurea 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Everolimus 2Carboplatin 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1talactoferrin alfa 1sargramostim 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Salivary Gland Neoplasms × Gene Expression Profiling × Clear all
NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Fox Chase Cancer Center

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡